BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: van Kessel SP, Frye AK, El-Gendy AO, Castejon M, Keshavarzian A, van Dijk G, El Aidy S. Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson's disease. Nat Commun 2019;10:310. [PMID: 30659181 DOI: 10.1038/s41467-019-08294-y] [Cited by in Crossref: 127] [Cited by in F6Publishing: 153] [Article Influence: 42.3] [Reference Citation Analysis]
Number Citing Articles
1 Lin CH, Lai HC, Wu MS. Gut-oriented disease modifying therapy for Parkinson's disease. J Formos Med Assoc 2022:S0929-6646(22)00360-6. [PMID: 36182642 DOI: 10.1016/j.jfma.2022.09.010] [Reference Citation Analysis]
2 Wang C, Cancino A, Baste J, Marten D, Joshi AA, Nasreen A, Bhushan A. Causative Role of Anoxic Environment in Bacterial Regulation of Human Intestinal Function. Cel Mol Bioeng . [DOI: 10.1007/s12195-022-00735-x] [Reference Citation Analysis]
3 Effendi SSW, Ng I. Reprogramming T7RNA Polymerase in Escherichia coli Nissle 1917 under Specific Lac Operon for Efficient p -Coumaric Acid Production. ACS Synth Biol . [DOI: 10.1021/acssynbio.2c00363] [Reference Citation Analysis]
4 Chen SJ, Lin CH. Gut microenvironmental changes as a potential trigger in Parkinson's disease through the gut-brain axis. J Biomed Sci 2022;29:54. [PMID: 35897024 DOI: 10.1186/s12929-022-00839-6] [Reference Citation Analysis]
5 Barone M, D'Amico F, Rampelli S, Brigidi P, Turroni S. Age-related diseases, therapies and gut microbiome: A new frontier for healthy aging. Mech Ageing Dev 2022;206:111711. [PMID: 35868543 DOI: 10.1016/j.mad.2022.111711] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Fan HX, Sheng S, Zhang F. New hope for Parkinson's disease treatment: Targeting gut microbiota. CNS Neurosci Ther 2022. [PMID: 35822696 DOI: 10.1111/cns.13916] [Reference Citation Analysis]
7 Walker ME, Simpson JB, Redinbo MR. A structural metagenomics pipeline for examining the gut microbiome. Curr Opin Struct Biol 2022;75:102416. [PMID: 35841748 DOI: 10.1016/j.sbi.2022.102416] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Liu J, Tan Y, Cheng H, Zhang D, Feng W, Peng C. Functions of Gut Microbiota Metabolites, Current Status and Future Perspectives. Aging Dis 2022;13:1106-26. [PMID: 35855347 DOI: 10.14336/AD.2022.0104] [Cited by in Crossref: 1] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
9 Han S, Shin J. Aromatic L-amino acid decarboxylases: mechanistic features and microbial applications. Appl Microbiol Biotechnol. [DOI: 10.1007/s00253-022-12028-4] [Reference Citation Analysis]
10 Tan AH, Lim SY, Lang AE. The microbiome-gut-brain axis in Parkinson disease - from basic research to the clinic. Nat Rev Neurol 2022. [PMID: 35750883 DOI: 10.1038/s41582-022-00681-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
11 Zhu M, Liu X, Ye Y, Yan X, Cheng Y, Zhao L, Chen F, Ling Z. Gut Microbiota: A Novel Therapeutic Target for Parkinson’s Disease. Front Immunol 2022;13:937555. [DOI: 10.3389/fimmu.2022.937555] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
12 Rich BE, Jackson JC, de Ora LO, Long ZG, Uyeda KS, Bess EN. Alternative pathway for dopamine production by acetogenic gut bacteria that O-Demethylate 3-Methoxytyramine, a metabolite of catechol O-Methyltransferase. J Appl Microbiol 2022. [PMID: 35737746 DOI: 10.1111/jam.15682] [Reference Citation Analysis]
13 Lee N, Kim D. Toxic Metabolites and Inborn Errors of Amino Acid Metabolism: What One Informs about the Other. Metabolites 2022;12:527. [PMID: 35736461 DOI: 10.3390/metabo12060527] [Reference Citation Analysis]
14 Cheng WY, Ho YS, Chang RC. Linking circadian rhythms to microbiome-gut-brain axis in aging-associated neurodegenerative diseases. Ageing Res Rev 2022;78:101620. [PMID: 35405323 DOI: 10.1016/j.arr.2022.101620] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
15 Stachulski AV, Knausenberger TB, Shah SN, Hoyles L, McArthur S. A host-gut microbial amino acid co-metabolite, p-cresol glucuronide, promotes blood-brain barrier integrity in vivo. Tissue Barriers 2022;:2073175. [PMID: 35596559 DOI: 10.1080/21688370.2022.2073175] [Reference Citation Analysis]
16 Pavan S, Prabhu AN, Prasad Gorthi S, Das B, Mutreja A, Shetty V, Ramamurthy T, Ballal M. Exploring the multifactorial aspects of Gut Microbiome in Parkinson's Disease. Folia Microbiol (Praha) 2022. [PMID: 35583791 DOI: 10.1007/s12223-022-00977-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Lubomski M, Xu X, Holmes AJ, Muller S, Yang JYH, Davis RL, Sue CM. The Gut Microbiome in Parkinson’s Disease: A Longitudinal Study of the Impacts on Disease Progression and the Use of Device-Assisted Therapies. Front Aging Neurosci 2022;14:875261. [DOI: 10.3389/fnagi.2022.875261] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Lubomski M, Xu X, Holmes AJ, Muller S, Yang JYH, Davis RL, Sue CM. Nutritional Intake and Gut Microbiome Composition Predict Parkinson’s Disease. Front Aging Neurosci 2022;14:881872. [DOI: 10.3389/fnagi.2022.881872] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
19 Beckers M, Bloem BR, Verbeek MM. Mechanisms of peripheral levodopa resistance in Parkinson's disease. NPJ Parkinsons Dis 2022;8:56. [PMID: 35546556 DOI: 10.1038/s41531-022-00321-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Ganesan R, Jeong J, Kim DJ, Suk KT. Recent Trends of Microbiota-Based Microbial Metabolites Metabolism in Liver Disease. Front Med 2022;9:841281. [DOI: 10.3389/fmed.2022.841281] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 Gonçalves S, Nunes-Costa D, Cardoso SM, Empadinhas N, Marugg JD. Enzyme Promiscuity in Serotonin Biosynthesis, From Bacteria to Plants and Humans. Front Microbiol 2022;13:873555. [PMID: 35495641 DOI: 10.3389/fmicb.2022.873555] [Reference Citation Analysis]
22 Shandilya S, Kumar S, Kumar Jha N, Kumar Kesari K, Ruokolainen J. Interplay of gut microbiota and oxidative stress: Perspective on neurodegeneration and neuroprotection. Journal of Advanced Research 2022;38:223-44. [DOI: 10.1016/j.jare.2021.09.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
23 Zhang Y, He X, Qian Y, Xu S, Mo C, Yan Z, Yang X, Xiao Q. Plasma branched-chain and aromatic amino acids correlate with the gut microbiota and severity of Parkinson's disease. NPJ Parkinsons Dis 2022;8:48. [PMID: 35449203 DOI: 10.1038/s41531-022-00312-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
24 Araujo de Oliveira AP, Romero Colmenares VC, Diniz R, Freitas JTJ, da Cruz CM, Lages EB, Ferreira LAM, Vieira RP, Beraldo H. Memantine-Derived Schiff Bases as Transdermal Prodrug Candidates. ACS Omega 2022;7:11678-87. [PMID: 35449959 DOI: 10.1021/acsomega.1c06571] [Reference Citation Analysis]
25 Peng H, Yu S, Zhang Y, Yin Y, Zhou J. Intestinal Dopamine Receptor D2 is Required for Neuroprotection Against 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Dopaminergic Neurodegeneration. Neurosci Bull . [DOI: 10.1007/s12264-022-00848-3] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
26 Guo T, Chen L. Gut microbiota and inflammation in Parkinson’s disease: Pathogenetic and therapeutic insights. Eur J Inflamm 2022;20:1721727X2210837. [DOI: 10.1177/1721727x221083763] [Reference Citation Analysis]
27 Warnecke T, Schäfer KH, Claus I, Del Tredici K, Jost WH. Gastrointestinal involvement in Parkinson's disease: pathophysiology, diagnosis, and management. NPJ Parkinsons Dis 2022;8:31. [PMID: 35332158 DOI: 10.1038/s41531-022-00295-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
28 Liu H, Cheng G, Xu Y, Fang Q, Ye L, Wang C, Liu X. Preoperative Status of Gut Microbiota Predicts Postoperative Delirium in Patients With Gastric Cancer. Front Psychiatry 2022;13:852269. [DOI: 10.3389/fpsyt.2022.852269] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
29 Awad A, Madla CM, McCoubrey LE, Ferraro F, Gavins FKH, Buanz A, Gaisford S, Orlu M, Siepmann F, Siepmann J, Basit AW. Clinical translation of advanced colonic drug delivery technologies. Adv Drug Deliv Rev 2022;181:114076. [PMID: 34890739 DOI: 10.1016/j.addr.2021.114076] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
30 van Kessel SP, Bullock A, van Dijk G, El Aidy S. Parkinson's Disease Medication Alters Small Intestinal Motility and Microbiota Composition in Healthy Rats. mSystems 2022;:e0119121. [PMID: 35076270 DOI: 10.1128/msystems.01191-21] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
31 Safarpour D, Sharzehi K, Pfeiffer RF. Gastrointestinal Dysfunction in Parkinson’s Disease. Drugs. [DOI: 10.1007/s40265-021-01664-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
32 Anis E, Xie A, Brundin L, Brundin P. Digesting recent findings: gut alpha-synuclein, microbiome changes in Parkinson's disease. Trends Endocrinol Metab 2021:S1043-2760(21)00268-X. [PMID: 34949514 DOI: 10.1016/j.tem.2021.11.005] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
33 van Kessel SP, Auvinen P, Scheperjans F, El Aidy S. Gut bacterial tyrosine decarboxylase associates with clinical variables in a longitudinal cohort study of Parkinsons disease. NPJ Parkinsons Dis 2021;7:115. [PMID: 34911958 DOI: 10.1038/s41531-021-00260-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
34 Grimm LM, Sinn S, Krstić M, D'Este E, Sonntag I, Prasetyanto EA, Kuner T, Wenzel W, De Cola L, Biedermann F. Fluorescent Nanozeolite Receptors for the Highly Selective and Sensitive Detection of Neurotransmitters in Water and Biofluids. Adv Mater 2021;33:e2104614. [PMID: 34580934 DOI: 10.1002/adma.202104614] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
35 Khedr EM, Ali AM, Deaf E, Hassan HM, Alaa A, Gamea A. Gut microbiota in Parkinson’s disease patients: hospital-based study. Egypt J Neurol Psychiatry Neurosurg 2021;57. [DOI: 10.1186/s41983-021-00407-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Pereira TMC, Côco LZ, Ton AMM, Meyrelles SS, Campos-Toimil M, Campagnaro BP, Vasquez EC. The Emerging Scenario of the Gut-Brain Axis: The Therapeutic Actions of the New Actor Kefir against Neurodegenerative Diseases. Antioxidants (Basel) 2021;10:1845. [PMID: 34829716 DOI: 10.3390/antiox10111845] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
37 El-Shehawy R, Luecke-Johansson S, Ribbenstedt A, Gorokhova E. Microbiota-Dependent and -Independent Production of l-Dopa in the Gut of Daphnia magna. mSystems 2021;:e0089221. [PMID: 34751589 DOI: 10.1128/mSystems.00892-21] [Reference Citation Analysis]
38 Radhakrishnan ST, Alexander JL, Mullish BH, Gallagher KI, Powell N, Hicks LC, Hart AL, Li JV, Marchesi JR, Williams HRT. Systematic review: the association between the gut microbiota and medical therapies in inflammatory bowel disease. Aliment Pharmacol Ther 2021. [PMID: 34751954 DOI: 10.1111/apt.16656] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
39 Dănău A, Dumitrescu L, Lefter A, Tulbă D, Popescu BO. Small Intestinal Bacterial Overgrowth as Potential Therapeutic Target in Parkinson's Disease. Int J Mol Sci 2021;22:11663. [PMID: 34769091 DOI: 10.3390/ijms222111663] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
40 Shen S, Zhang C, Xu YM, Shi CH. The Role of Pathogens and Anti-Infective Agents in Parkinson's Disease, from Etiology to Therapeutic Implications. J Parkinsons Dis 2021. [PMID: 34719435 DOI: 10.3233/JPD-212929] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
41 Klatt S, Doecke JD, Roberts A, Boughton BA, Masters CL, Horne M, Roberts BR. A six-metabolite panel as potential blood-based biomarkers for Parkinson's disease. NPJ Parkinsons Dis 2021;7:94. [PMID: 34650080 DOI: 10.1038/s41531-021-00239-x] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
42 Snigdha S, Ha K, Tsai P, Dinan TG, Bartos JD, Shahid M. Probiotics: Potential novel therapeutics for microbiota-gut-brain axis dysfunction across gender and lifespan. Pharmacol Ther 2021;:107978. [PMID: 34492236 DOI: 10.1016/j.pharmthera.2021.107978] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
43 Jie Z, Liang S, Ding Q, Li F, Sun X, Lin Y, Chen P, Cai K, Zhou H, Lu H, Wang X, Zhang T, Xiao L, Yang H, Wang J, Hou Y, Kristiansen K, Jia H, Xu X. Disease trends in a young Chinese cohort according to fecal metagenome and plasma metabolites. Medicine in Microecology 2021;9:100037. [DOI: 10.1016/j.medmic.2021.100037] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
44 Munoz-Pinto MF, Empadinhas N, Cardoso SM. The neuromicrobiology of Parkinson's disease: A unifying theory. Ageing Res Rev 2021;70:101396. [PMID: 34171417 DOI: 10.1016/j.arr.2021.101396] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
45 Milošević M, Arsić A, Cvetković Z, Vučić V. Memorable Food: Fighting Age-Related Neurodegeneration by Precision Nutrition. Front Nutr 2021;8:688086. [PMID: 34422879 DOI: 10.3389/fnut.2021.688086] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
46 Lei Q, Wu T, Wu J, Hu X, Guan Y, Wang Y, Yan J, Shi G. Roles of α‑synuclein in gastrointestinal microbiome dysbiosis‑related Parkinson's disease progression (Review). Mol Med Rep 2021;24:734. [PMID: 34414447 DOI: 10.3892/mmr.2021.12374] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
47 Desselberger U. Significance of the Gut Microbiome for Viral Diarrheal and Extra-Intestinal Diseases. Viruses 2021;13:1601. [PMID: 34452466 DOI: 10.3390/v13081601] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
48 Zheng SY, Li HX, Xu RC, Miao WT, Dai MY, Ding ST, Liu HD. Potential roles of gut microbiota and microbial metabolites in Parkinson's disease. Ageing Res Rev 2021;69:101347. [PMID: 33905953 DOI: 10.1016/j.arr.2021.101347] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
49 Kelly JR, Minuto C, Cryan JF, Clarke G, Dinan TG. The role of the gut microbiome in the development of schizophrenia. Schizophrenia Research 2021;234:4-23. [DOI: 10.1016/j.schres.2020.02.010] [Cited by in Crossref: 13] [Cited by in F6Publishing: 25] [Article Influence: 13.0] [Reference Citation Analysis]
50 Li S, Jia C, Li T, Le W. Hot Topics in Recent Parkinson's Disease Research: Where We are and Where We Should Go. Neurosci Bull 2021. [PMID: 34313916 DOI: 10.1007/s12264-021-00749-x] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
51 Drobny A, Ngo PA, Neurath MF, Zunke F, López-Posadas R. Molecular Communication Between Neuronal Networks and Intestinal Epithelial Cells in Gut Inflammation and Parkinson's Disease. Front Med (Lausanne) 2021;8:655123. [PMID: 34368179 DOI: 10.3389/fmed.2021.655123] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
52 Jia B, Han X, Kim KH, Jeon CO. Discovery and mining of enzymes from the human gut microbiome. Trends Biotechnol 2021:S0167-7799(21)00138-4. [PMID: 34304905 DOI: 10.1016/j.tibtech.2021.06.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
53 Mirzaei H, Sedighi S, Kouchaki E, Barati E, Dadgostar E, Aschner M, Tamtaji OR. Probiotics and the Treatment of Parkinson's Disease: An Update. Cell Mol Neurobiol 2021. [PMID: 34283340 DOI: 10.1007/s10571-021-01128-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
54 Wang C, Dang T, Baste J, Anil Joshi A, Bhushan A. A novel standalone microfluidic device for local control of oxygen tension for intestinal-bacteria interactions. FASEB J 2021;35:e21291. [PMID: 33506497 DOI: 10.1096/fj.202001600RR] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
55 Tan LY, Yeo XY, Bae HG, Lee DPS, Ho RC, Kim JE, Jo DG, Jung S. Association of Gut Microbiome Dysbiosis with Neurodegeneration: Can Gut Microbe-Modifying Diet Prevent or Alleviate the Symptoms of Neurodegenerative Diseases? Life (Basel) 2021;11:698. [PMID: 34357070 DOI: 10.3390/life11070698] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
56 McCoubrey LE, Gaisford S, Orlu M, Basit AW. Predicting drug-microbiome interactions with machine learning. Biotechnol Adv 2021;:107797. [PMID: 34260950 DOI: 10.1016/j.biotechadv.2021.107797] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 15.0] [Reference Citation Analysis]
57 Auffret M, Meuric V, Boyer E, Bonnaure-Mallet M, Vérin M. Oral Health Disorders in Parkinson's Disease: More than Meets the Eye. J Parkinsons Dis 2021. [PMID: 34250950 DOI: 10.3233/JPD-212605] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
58 Kim YC, Lee J, Park JH, Mah JH, Kim SY, Kim YW. Development of a colorimetric enzymatic assay method for aromatic biogenic monoamine-producing decarboxylases. Food Sci Biotechnol 2021;30:971-7. [PMID: 34395028 DOI: 10.1007/s10068-021-00938-4] [Reference Citation Analysis]
59 Lubomski M, Xu X, Holmes AJ, Yang JYH, Sue CM, Davis RL. The impact of device-assisted therapies on the gut microbiome in Parkinson's disease. J Neurol 2021. [PMID: 34128115 DOI: 10.1007/s00415-021-10657-9] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
60 Chen J, Wang A, Wang Q. Dysbiosis of the gut microbiome is a risk factor for osteoarthritis in older female adults: a case control study. BMC Bioinformatics 2021;22:299. [PMID: 34082693 DOI: 10.1186/s12859-021-04199-0] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
61 Jie Z, Liang S, Ding Q, Li F, Tang S, Wang D, Lin Y, Chen P, Cai K, Qiu X, Li Q, Liao Y, Zhou D, Lian H, Zuo Y, Chen X, Rao W, Ren Y, Wang Y, Zi J, Wang R, Zhou H, Lu H, Wang X, Zhang W, Zhang T, Xiao L, Zong Y, Liu W, Yang H, Wang J, Hou Y, Liu X, Kristiansen K, Zhong H, Jia H, Xu X. A transomic cohort as a reference point for promoting a healthy human gut microbiome. Medicine in Microecology 2021;8:100039. [DOI: 10.1016/j.medmic.2021.100039] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
62 Guo Y, Zhu X, Zeng M, Qi L, Tang X, Wang D, Zhang M, Xie Y, Li H, Yang X, Chen D. A diet high in sugar and fat influences neurotransmitter metabolism and then affects brain function by altering the gut microbiota. Transl Psychiatry 2021;11:328. [PMID: 34045460 DOI: 10.1038/s41398-021-01443-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
63 Duan J, Huang Y, Tan X, Chai T, Wu J, Zhang H, Li Y, Hu X, Zheng P, Ji P, Zhao L, Yang D, Fang L, Song J, Xie P. Characterization of gut microbiome in mice model of depression with divergent response to escitalopram treatment. Transl Psychiatry 2021;11:303. [PMID: 34016954 DOI: 10.1038/s41398-021-01428-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 10.0] [Reference Citation Analysis]
64 Fang P, Kazmi SA, Jameson KG, Hsiao EY. The Microbiome as a Modifier of Neurodegenerative Disease Risk. Cell Host Microbe 2020;28:201-22. [PMID: 32791113 DOI: 10.1016/j.chom.2020.06.008] [Cited by in Crossref: 11] [Cited by in F6Publishing: 43] [Article Influence: 11.0] [Reference Citation Analysis]
65 Tsunoda SM, Gonzales C, Jarmusch AK, Momper JD, Ma JD. Contribution of the Gut Microbiome to Drug Disposition, Pharmacokinetic and Pharmacodynamic Variability. Clin Pharmacokinet 2021;60:971-84. [PMID: 33959897 DOI: 10.1007/s40262-021-01032-y] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
66 Chen X, Meng S, Li S, Zhang L, Wu L, Zhu H, Zhang Y. Role of 5-Hydroxytryptamine and Intestinal Flora on Depressive-Like Behavior Induced by Lead Exposure in Rats. Biomed Res Int 2021;2021:5516604. [PMID: 33996997 DOI: 10.1155/2021/5516604] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
67 Sharma P, Agrawal A. Does modern research validate the ancient wisdom of gut flora and brain connection? A literature review of gut dysbiosis in neurological and neurosurgical disorders over the last decade. Neurosurg Rev 2021. [PMID: 33904013 DOI: 10.1007/s10143-021-01516-2] [Reference Citation Analysis]
68 Zhang X, Cheng K, Ning Z, Mayne J, Walker K, Chi H, Farnsworth CL, Lee K, Figeys D. Exploring the Microbiome-Wide Lysine Acetylation, Succinylation, and Propionylation in Human Gut Microbiota. Anal Chem 2021;93:6594-8. [PMID: 33885279 DOI: 10.1021/acs.analchem.1c00962] [Reference Citation Analysis]
69 Metta V, Leta V, Mrudula KR, Prashanth LK, Goyal V, Borgohain R, Chung-Faye G, Chaudhuri KR. Gastrointestinal dysfunction in Parkinson's disease: molecular pathology and implications of gut microbiome, probiotics, and fecal microbiota transplantation. J Neurol 2021. [PMID: 33881598 DOI: 10.1007/s00415-021-10567-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 17] [Article Influence: 1.0] [Reference Citation Analysis]
70 Menozzi E, Macnaughtan J, Schapira AHV. The gut-brain axis and Parkinson disease: clinical and pathogenetic relevance. Ann Med 2021;53:611-25. [PMID: 33860738 DOI: 10.1080/07853890.2021.1890330] [Cited by in Crossref: 2] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
71 Luo Y, Zhou T. Connecting the dots: Targeting the microbiome in drug toxicity. Med Res Rev 2021. [PMID: 33856076 DOI: 10.1002/med.21805] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
72 Bloem BR, Okun MS, Klein C. Parkinson's disease. Lancet 2021;397:2284-303. [PMID: 33848468 DOI: 10.1016/S0140-6736(21)00218-X] [Cited by in Crossref: 22] [Cited by in F6Publishing: 201] [Article Influence: 22.0] [Reference Citation Analysis]
73 Vinarov Z, Abrahamsson B, Artursson P, Batchelor H, Berben P, Bernkop-Schnürch A, Butler J, Ceulemans J, Davies N, Dupont D, Flaten GE, Fotaki N, Griffin BT, Jannin V, Keemink J, Kesisoglou F, Koziolek M, Kuentz M, Mackie A, Meléndez-Martínez AJ, McAllister M, Müllertz A, O'Driscoll CM, Parrott N, Paszkowska J, Pavek P, Porter CJH, Reppas C, Stillhart C, Sugano K, Toader E, Valentová K, Vertzoni M, De Wildt SN, Wilson CG, Augustijns P. Current challenges and future perspectives in oral absorption research: An opinion of the UNGAP network. Adv Drug Deliv Rev 2021;171:289-331. [PMID: 33610694 DOI: 10.1016/j.addr.2021.02.001] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 30.0] [Reference Citation Analysis]
74 Ojeda J, Ávila A, Vidal PM. Gut Microbiota Interaction with the Central Nervous System throughout Life. J Clin Med 2021;10:1299. [PMID: 33801153 DOI: 10.3390/jcm10061299] [Cited by in Crossref: 3] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
75 Vinarov Z, Abdallah M, Agundez JAG, Allegaert K, Basit AW, Braeckmans M, Ceulemans J, Corsetti M, Griffin BT, Grimm M, Keszthelyi D, Koziolek M, Madla CM, Matthys C, McCoubrey LE, Mitra A, Reppas C, Stappaerts J, Steenackers N, Trevaskis NL, Vanuytsel T, Vertzoni M, Weitschies W, Wilson C, Augustijns P. Impact of gastrointestinal tract variability on oral drug absorption and pharmacokinetics: An UNGAP review. Eur J Pharm Sci 2021;162:105812. [PMID: 33753215 DOI: 10.1016/j.ejps.2021.105812] [Cited by in Crossref: 9] [Cited by in F6Publishing: 47] [Article Influence: 9.0] [Reference Citation Analysis]
76 Lorente-Picón M, Laguna A. New Avenues for Parkinson's Disease Therapeutics: Disease-Modifying Strategies Based on the Gut Microbiota. Biomolecules 2021;11:433. [PMID: 33804226 DOI: 10.3390/biom11030433] [Cited by in Crossref: 3] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
77 Romano S, Savva GM, Bedarf JR, Charles IG, Hildebrand F, Narbad A. Meta-analysis of the Parkinson's disease gut microbiome suggests alterations linked to intestinal inflammation. NPJ Parkinsons Dis 2021;7:27. [PMID: 33692356 DOI: 10.1038/s41531-021-00156-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 100] [Article Influence: 19.0] [Reference Citation Analysis]
78 Palacios N, Hannoun A, Flahive J, Ward D, Goostrey K, Deb A, Smith KM. Effect of Levodopa Initiation on the Gut Microbiota in Parkinson's Disease. Front Neurol 2021;12:574529. [PMID: 33746867 DOI: 10.3389/fneur.2021.574529] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
79 Ryu G, Kim H, Koh A. Approaching precision medicine by tailoring the microbiota. Mamm Genome 2021;32:206-22. [PMID: 33646347 DOI: 10.1007/s00335-021-09859-3] [Reference Citation Analysis]
80 Reed X, Schumacher-Schuh A, Hu J, Bandres-Ciga S. Advancing Personalized Medicine in Common Forms of Parkinson's Disease through Genetics: Current Therapeutics and the Future of Individualized Management. J Pers Med 2021;11:169. [PMID: 33804504 DOI: 10.3390/jpm11030169] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
81 McCoubrey LE, Elbadawi M, Orlu M, Gaisford S, Basit AW. Harnessing machine learning for development of microbiome therapeutics. Gut Microbes 2021;13:1-20. [PMID: 33522391 DOI: 10.1080/19490976.2021.1872323] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 26.0] [Reference Citation Analysis]
82 Tran SM, Mohajeri MH. The Role of Gut Bacterial Metabolites in Brain Development, Aging and Disease. Nutrients 2021;13:732. [PMID: 33669008 DOI: 10.3390/nu13030732] [Cited by in Crossref: 4] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
83 Nyholm D, Hellström PM. Effects of Helicobacter pylori on Levodopa Pharmacokinetics. J Parkinsons Dis 2021;11:61-9. [PMID: 33164946 DOI: 10.3233/JPD-202298] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
84 Skjærbæk C, Knudsen K, Horsager J, Borghammer P. Gastrointestinal Dysfunction in Parkinson's Disease. J Clin Med 2021;10:493. [PMID: 33572547 DOI: 10.3390/jcm10030493] [Cited by in Crossref: 5] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
85 Vascellari S, Melis M, Palmas V, Pisanu S, Serra A, Perra D, Santoru ML, Oppo V, Cusano R, Uva P, Atzori L, Morelli M, Cossu G, Manzin A. Clinical Phenotypes of Parkinson's Disease Associate with Distinct Gut Microbiota and Metabolome Enterotypes. Biomolecules 2021;11:144. [PMID: 33499229 DOI: 10.3390/biom11020144] [Cited by in Crossref: 4] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
86 Waclawiková B, Bullock A, Schwalbe M, Aranzamendi C, Nelemans SA, van Dijk G, El Aidy S. Gut bacteria-derived 5-hydroxyindole is a potent stimulant of intestinal motility via its action on L-type calcium channels. PLoS Biol 2021;19:e3001070. [PMID: 33481771 DOI: 10.1371/journal.pbio.3001070] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
87 Boddy SL, Giovannelli I, Sassani M, Cooper-Knock J, Snyder MP, Segal E, Elinav E, Barker LA, Shaw PJ, McDermott CJ. The gut microbiome: a key player in the complexity of amyotrophic lateral sclerosis (ALS). BMC Med 2021;19:13. [PMID: 33468103 DOI: 10.1186/s12916-020-01885-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
88 Jansma J, El Aidy S. Understanding the host-microbe interactions using metabolic modeling. Microbiome 2021;9:16. [PMID: 33472685 DOI: 10.1186/s40168-020-00955-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 17] [Article Influence: 1.0] [Reference Citation Analysis]
89 Nguyen VTT, Sallbach J, Dos Santos Guilherme M, Endres K. Influence of Acetylcholine Esterase Inhibitors and Memantine, Clinically Approved for Alzheimer's Dementia Treatment, on Intestinal Properties of the Mouse. Int J Mol Sci 2021;22:1015. [PMID: 33498392 DOI: 10.3390/ijms22031015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
90 Xu HM, Huang HL, Zhou YL, Zhao HL, Xu J, Shou DW, Liu YD, Zhou YJ, Nie YQ. Fecal Microbiota Transplantation: A New Therapeutic Attempt from the Gut to the Brain. Gastroenterol Res Pract 2021;2021:6699268. [PMID: 33510784 DOI: 10.1155/2021/6699268] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 20.0] [Reference Citation Analysis]
91 Rajput C, Sarkar A, Sachan N, Rawat N, Singh MP. Is Gut Dysbiosis an Epicenter of Parkinson's Disease? Neurochem Res 2021;46:425-38. [PMID: 33400024 DOI: 10.1007/s11064-020-03187-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
92 Castelli V, d'Angelo M, Quintiliani M, Benedetti E, Cifone MG, Cimini A. The emerging role of probiotics in neurodegenerative diseases: new hope for Parkinson's disease? Neural Regen Res 2021;16:628-34. [PMID: 33063712 DOI: 10.4103/1673-5374.295270] [Cited by in Crossref: 8] [Cited by in F6Publishing: 19] [Article Influence: 8.0] [Reference Citation Analysis]
93 Kaur G, Behl T, Bungau S, Kumar A, Uddin MS, Mehta V, Zengin G, Mathew B, Shah MA, Arora S. Dysregulation of the Gut-Brain Axis, Dysbiosis and Influence of Numerous Factors on Gut Microbiota Associated Parkinson's Disease. Curr Neuropharmacol 2021;19:233-47. [PMID: 32504503 DOI: 10.2174/1570159X18666200606233050] [Cited by in Crossref: 9] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
94 Ling Z, Liu X, Cheng Y, Yan X, Wu S. Gut microbiota and aging. Crit Rev Food Sci Nutr 2020;:1-56. [PMID: 33377391 DOI: 10.1080/10408398.2020.1867054] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
95 Jaskiw GE, Obrenovich ME, Kundrapu S, Donskey CJ. Changes in the Serum Metabolome of Patients Treated With Broad-Spectrum Antibiotics. Pathog Immun 2020;5:382-418. [PMID: 33474520 DOI: 10.20411/pai.v5i1.394] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
96 Majcher MJ, Babar A, Lofts A, Leung A, Li X, Abu-Hijleh F, Smeets NMB, Mishra RK, Hoare T. In situ-gelling starch nanoparticle (SNP)/O-carboxymethyl chitosan (CMCh) nanoparticle network hydrogels for the intranasal delivery of an antipsychotic peptide. J Control Release 2021;330:738-52. [PMID: 33383097 DOI: 10.1016/j.jconrel.2020.12.050] [Cited by in Crossref: 3] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
97 Melis M, Vascellari S, Santoru ML, Oppo V, Fabbri M, Sarchioto M, Murgia D, Zibetti M, Lopiano L, Serra A, Palmas V, Pisanu S, Perra D, Madau V, Cusano R, Uva P, Mereu A, Contu P, Morelli M, Atzori L, Melis M, Manzin A, Cossu G. Gut microbiota and metabolome distinctive features in Parkinson disease: Focus on levodopa and levodopa-carbidopa intrajejunal gel. Eur J Neurol 2021;28:1198-209. [PMID: 33185912 DOI: 10.1111/ene.14644] [Cited by in Crossref: 3] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
98 Hassan R, Allali I, Agamah FE, Elsheikh SSM, Thomford NE, Dandara C, Chimusa ER. Drug response in association with pharmacogenomics and pharmacomicrobiomics: towards a better personalized medicine. Brief Bioinform 2021;22:bbaa292. [PMID: 33253350 DOI: 10.1093/bib/bbaa292] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
99 Chung KA, Pfeiffer RF. Gastrointestinal dysfunction in the synucleinopathies. Clin Auton Res 2021;31:77-99. [PMID: 33247399 DOI: 10.1007/s10286-020-00745-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
100 Holingue C, Budavari AC, Rodriguez KM, Zisman CR, Windheim G, Fallin MD. Sex Differences in the Gut-Brain Axis: Implications for Mental Health. Curr Psychiatry Rep 2020;22:83. [PMID: 33216233 DOI: 10.1007/s11920-020-01202-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 14] [Article Influence: 0.5] [Reference Citation Analysis]
101 Tan AH, Hor JW, Chong CW, Lim SY. Probiotics for Parkinson's disease: Current evidence and future directions. JGH Open 2021;5:414-9. [PMID: 33860090 DOI: 10.1002/jgh3.12450] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
102 Liu J, Xu F, Nie Z, Shao L. Gut Microbiota Approach-A New Strategy to Treat Parkinson's Disease. Front Cell Infect Microbiol 2020;10:570658. [PMID: 33194809 DOI: 10.3389/fcimb.2020.570658] [Cited by in Crossref: 4] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
103 Morais LH, Schreiber HL 4th, Mazmanian SK. The gut microbiota-brain axis in behaviour and brain disorders. Nat Rev Microbiol 2021;19:241-55. [PMID: 33093662 DOI: 10.1038/s41579-020-00460-0] [Cited by in Crossref: 55] [Cited by in F6Publishing: 244] [Article Influence: 27.5] [Reference Citation Analysis]
104 Hopper CP, De La Cruz LK, Lyles KV, Wareham LK, Gilbert JA, Eichenbaum Z, Magierowski M, Poole RK, Wollborn J, Wang B. Role of Carbon Monoxide in Host-Gut Microbiome Communication. Chem Rev 2020;120:13273-311. [PMID: 33089988 DOI: 10.1021/acs.chemrev.0c00586] [Cited by in Crossref: 5] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
105 van Kessel SP, de Jong HR, Winkel SL, van Leeuwen SS, Nelemans SA, Permentier H, Keshavarzian A, El Aidy S. Gut bacterial deamination of residual levodopa medication for Parkinson's disease. BMC Biol 2020;18:137. [PMID: 33076930 DOI: 10.1186/s12915-020-00876-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
106 Unger MM, Becker A, Keller A, Schäfer KH, Schwiertz A, Oertel WH. [The role of the gut microbiome in idiopathic Parkinson's disease]. Nervenarzt 2020;91:1085-95. [PMID: 33025073 DOI: 10.1007/s00115-020-01011-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
107 Nogacka AM, de Los Reyes-Gavilán CG, Martínez-Faedo C, Ruas-Madiedo P, Suarez A, Mancabelli L, Ventura M, Cifuentes A, León C, Gueimonde M, Salazar N. Impact of Extreme Obesity and Diet-Induced Weight Loss on the Fecal Metabolome and Gut Microbiota. Mol Nutr Food Res 2021;65:e2000030. [PMID: 32966685 DOI: 10.1002/mnfr.202000030] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
108 Royes LFF. Cross-talk between gut and brain elicited by physical exercise. Biochim Biophys Acta Mol Basis Dis 2020;1866:165877. [PMID: 32544430 DOI: 10.1016/j.bbadis.2020.165877] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
109 Krautkramer KA, Fan J, Bäckhed F. Gut microbial metabolites as multi-kingdom intermediates. Nat Rev Microbiol 2021;19:77-94. [PMID: 32968241 DOI: 10.1038/s41579-020-0438-4] [Cited by in Crossref: 45] [Cited by in F6Publishing: 175] [Article Influence: 22.5] [Reference Citation Analysis]
110 Vascellari S, Palmas V, Melis M, Pisanu S, Cusano R, Uva P, Perra D, Madau V, Sarchioto M, Oppo V, Simola N, Morelli M, Santoru ML, Atzori L, Melis M, Cossu G, Manzin A. Gut Microbiota and Metabolome Alterations Associated with Parkinson's Disease. mSystems 2020;5:e00561-20. [PMID: 32934117 DOI: 10.1128/mSystems.00561-20] [Cited by in Crossref: 24] [Cited by in F6Publishing: 56] [Article Influence: 12.0] [Reference Citation Analysis]
111 Groot HE, van de Vegte YJ, Verweij N, Lipsic E, Karper JC, van der Harst P. Human genetic determinants of the gut microbiome and their associations with health and disease: a phenome-wide association study. Sci Rep 2020;10:14771. [PMID: 32901066 DOI: 10.1038/s41598-020-70724-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
112 Tan AH, Lim S, Mahadeva S, Loke MF, Tan JY, Ang BH, Chin KP, Mohammad Adnan AF, Ong SMC, Ibrahim AI, Zulkifli N, Lee JK, Lim WT, Teo YT, Kok YL, Ng TY, Tan AGS, Zulkifle IM, Ng CK, Ee SS, Arafin S, Mohamad Shukori K, Vadivelu JS, Marras C, Fox SH, Lang AE. Helicobacter pylori Eradication in Parkinson's Disease: A Randomized Placebo‐Controlled Trial. Mov Disord 2020;35:2250-60. [DOI: 10.1002/mds.28248] [Cited by in Crossref: 10] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
113 Bhattarai Y, Kashyap PC. Parkinson's disease: Are gut microbes involved? Am J Physiol Gastrointest Liver Physiol 2020;319:G529-40. [PMID: 32877215 DOI: 10.1152/ajpgi.00058.2020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
114 Henriques SF, Dhakan DB, Serra L, Francisco AP, Carvalho-Santos Z, Baltazar C, Elias AP, Anjos M, Zhang T, Maddocks ODK, Ribeiro C. Metabolic cross-feeding in imbalanced diets allows gut microbes to improve reproduction and alter host behaviour. Nat Commun 2020;11:4236. [PMID: 32843654 DOI: 10.1038/s41467-020-18049-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 31] [Article Influence: 7.5] [Reference Citation Analysis]
115 Xu X, Hu Y, Yan E, Zhan G, Liu C, Yang C. Perioperative neurocognitive dysfunction: thinking from the gut? Aging (Albany NY) 2020;12:15797-817. [PMID: 32805716 DOI: 10.18632/aging.103738] [Cited by in Crossref: 2] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
116 Pfeiffer RF. Autonomic Dysfunction in Parkinson's Disease. Neurotherapeutics 2020;17:1464-79. [PMID: 32789741 DOI: 10.1007/s13311-020-00897-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
117 Weersma RK, Zhernakova A, Fu J. Interaction between drugs and the gut microbiome. Gut 2020;69:1510-9. [PMID: 32409589 DOI: 10.1136/gutjnl-2019-320204] [Cited by in Crossref: 119] [Cited by in F6Publishing: 122] [Article Influence: 59.5] [Reference Citation Analysis]
118 van Kessel SP, El Aidy S. Bacterial Metabolites Mirror Altered Gut Microbiota Composition in Patients with Parkinson's Disease. J Parkinsons Dis 2019;9:S359-70. [PMID: 31609701 DOI: 10.3233/JPD-191780] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
119 Ceppa FA, Izzo L, Sardelli L, Raimondi I, Tunesi M, Albani D, Giordano C. Human Gut-Microbiota Interaction in Neurodegenerative Disorders and Current Engineered Tools for Its Modeling. Front Cell Infect Microbiol 2020;10:297. [PMID: 32733812 DOI: 10.3389/fcimb.2020.00297] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 6.5] [Reference Citation Analysis]
120 Flowers SA, Bhat S, Lee JC. Potential Implications of Gut Microbiota in Drug Pharmacokinetics and Bioavailability. Pharmacotherapy 2020;40:704-12. [DOI: 10.1002/phar.2428] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
121 Wu WK, Ivanova EA, Orekhov AN. Gut microbiome: A possible common therapeutic target for treatment of atherosclerosis and cancer. Semin Cancer Biol 2021;70:85-97. [PMID: 32610150 DOI: 10.1016/j.semcancer.2020.06.017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
122 Javdan B, Lopez JG, Chankhamjon P, Lee YJ, Hull R, Wu Q, Wang X, Chatterjee S, Donia MS. Personalized Mapping of Drug Metabolism by the Human Gut Microbiome. Cell 2020;181:1661-1679.e22. [PMID: 32526207 DOI: 10.1016/j.cell.2020.05.001] [Cited by in Crossref: 43] [Cited by in F6Publishing: 74] [Article Influence: 21.5] [Reference Citation Analysis]
123 Baldini F, Hertel J, Sandt E, Thinnes CC, Neuberger-Castillo L, Pavelka L, Betsou F, Krüger R, Thiele I; NCER-PD Consortium. Parkinson's disease-associated alterations of the gut microbiome predict disease-relevant changes in metabolic functions. BMC Biol 2020;18:62. [PMID: 32517799 DOI: 10.1186/s12915-020-00775-7] [Cited by in Crossref: 35] [Cited by in F6Publishing: 56] [Article Influence: 17.5] [Reference Citation Analysis]
124 Cortés-Martín A, Selma MV, Tomás-Barberán FA, González-Sarrías A, Espín JC. Where to Look into the Puzzle of Polyphenols and Health? The Postbiotics and Gut Microbiota Associated with Human Metabotypes. Mol Nutr Food Res 2020;64:e1900952. [PMID: 32196920 DOI: 10.1002/mnfr.201900952] [Cited by in Crossref: 39] [Cited by in F6Publishing: 69] [Article Influence: 19.5] [Reference Citation Analysis]
125 Chae S, Kim DJ, Cho JY. Complex influences of gut microbiome metabolism on various drug responses. Transl Clin Pharmacol 2020;28:7-16. [PMID: 32274377 DOI: 10.12793/tcp.2020.28.e3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
126 Vendrik KEW, Ooijevaar RE, de Jong PRC, Laman JD, van Oosten BW, van Hilten JJ, Ducarmon QR, Keller JJ, Kuijper EJ, Contarino MF. Fecal Microbiota Transplantation in Neurological Disorders. Front Cell Infect Microbiol 2020;10:98. [PMID: 32266160 DOI: 10.3389/fcimb.2020.00098] [Cited by in Crossref: 47] [Cited by in F6Publishing: 95] [Article Influence: 23.5] [Reference Citation Analysis]
127 Hegelmaier T, Lebbing M, Duscha A, Tomaske L, Tönges L, Holm JB, Bjørn Nielsen H, Gatermann SG, Przuntek H, Haghikia A. Interventional Influence of the Intestinal Microbiome Through Dietary Intervention and Bowel Cleansing Might Improve Motor Symptoms in Parkinson's Disease. Cells 2020;9:E376. [PMID: 32041265 DOI: 10.3390/cells9020376] [Cited by in Crossref: 13] [Cited by in F6Publishing: 22] [Article Influence: 6.5] [Reference Citation Analysis]
128 Ilie OD, Ciobica A, McKenna J, Doroftei B, Mavroudis I. Minireview on the Relations between Gut Microflora and Parkinson's Disease: Further Biochemical (Oxidative Stress), Inflammatory, and Neurological Particularities. Oxid Med Cell Longev 2020;2020:4518023. [PMID: 32089768 DOI: 10.1155/2020/4518023] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
129 Cryan JF, O'riordan KJ, Sandhu K, Peterson V, Dinan TG. The gut microbiome in neurological disorders. The Lancet Neurology 2020;19:179-94. [DOI: 10.1016/s1474-4422(19)30356-4] [Cited by in Crossref: 135] [Cited by in F6Publishing: 271] [Article Influence: 67.5] [Reference Citation Analysis]
130 Brüssow H. Parkinson disease, levodopa and the gut microbiota-when microbiology meets pharmacology. Environ Microbiol 2020;22:808-12. [PMID: 31950559 DOI: 10.1111/1462-2920.14919] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
131 Jariwala PB, Pellock SJ, Goldfarb D, Cloer EW, Artola M, Simpson JB, Bhatt AP, Walton WG, Roberts LR, Major MB, Davies GJ, Overkleeft HS, Redinbo MR. Discovering the Microbial Enzymes Driving Drug Toxicity with Activity-Based Protein Profiling. ACS Chem Biol 2020;15:217-25. [PMID: 31774274 DOI: 10.1021/acschembio.9b00788] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 13.0] [Reference Citation Analysis]
132 Zheng W, He R, Yan Z, Huang Y, Huang W, Cai Z, Su Y, Liu S, Deng Y, Wang Q, Xie H. Regulation of immune-driven pathogenesis in Parkinson's disease by gut microbiota. Brain Behav Immun 2020;87:890-7. [PMID: 31931152 DOI: 10.1016/j.bbi.2020.01.009] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
133 Bugda Gwilt K, González DP, Olliffe N, Oller H, Hoffing R, Puzan M, El Aidy S, Miller GM. Actions of Trace Amines in the Brain-Gut-Microbiome Axis via Trace Amine-Associated Receptor-1 (TAAR1). Cell Mol Neurobiol 2020;40:191-201. [DOI: 10.1007/s10571-019-00772-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
134 Weis S, Schwiertz A, Unger MM, Becker A, Faßbender K, Ratering S, Kohl M, Schnell S, Schäfer KH, Egert M. Effect of Parkinson's disease and related medications on the composition of the fecal bacterial microbiota. NPJ Parkinsons Dis 2019;5:28. [PMID: 31815177 DOI: 10.1038/s41531-019-0100-x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 39] [Article Influence: 7.7] [Reference Citation Analysis]
135 Lam KN, Alexander M, Turnbaugh PJ. Precision Medicine Goes Microscopic: Engineering the Microbiome to Improve Drug Outcomes. Cell Host Microbe 2019;26:22-34. [PMID: 31295421 DOI: 10.1016/j.chom.2019.06.011] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 14.0] [Reference Citation Analysis]
136 Maini Rekdal V, Bess EN, Bisanz JE, Turnbaugh PJ, Balskus EP. Discovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism. Science 2019;364:eaau6323. [PMID: 31196984 DOI: 10.1126/science.aau6323] [Cited by in Crossref: 159] [Cited by in F6Publishing: 178] [Article Influence: 53.0] [Reference Citation Analysis]
137 Adams JB, Borody TJ, Kang D, Khoruts A, Krajmalnik-brown R, Sadowsky MJ. Microbiota transplant therapy and autism: lessons for the clinic. Expert Review of Gastroenterology & Hepatology 2019;13:1033-7. [DOI: 10.1080/17474124.2019.1687293] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
138 Bullich C, Keshavarzian A, Garssen J, Kraneveld A, Perez-Pardo P. Gut Vibes in Parkinson's Disease: The Microbiota-Gut-Brain Axis. Mov Disord Clin Pract 2019;6:639-51. [PMID: 31745471 DOI: 10.1002/mdc3.12840] [Cited by in Crossref: 20] [Cited by in F6Publishing: 31] [Article Influence: 6.7] [Reference Citation Analysis]
139 van Kessel SP, El Aidy S. Contributions of Gut Bacteria and Diet to Drug Pharmacokinetics in the Treatment of Parkinson's Disease. Front Neurol 2019;10:1087. [PMID: 31681153 DOI: 10.3389/fneur.2019.01087] [Cited by in Crossref: 5] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
140 Singh Y, El-Hadidi M, Admard J, Wassouf Z, Schulze-Hentrich JM, Kohlhofer U, Quintanilla-Martinez L, Huson D, Riess O, Casadei N. Enriched Environmental Conditions Modify the Gut Microbiome Composition and Fecal Markers of Inflammation in Parkinson's Disease. Front Neurosci 2019;13:1032. [PMID: 31749671 DOI: 10.3389/fnins.2019.01032] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
141 Bugda Gwilt K, Olliffe N, Hoffing RA, Miller GM. Trace amine associated receptor 1 (TAAR1) expression and modulation of inflammatory cytokine production in mouse bone marrow-derived macrophages: a novel mechanism for inflammation in ulcerative colitis. Immunopharmacology and Immunotoxicology 2019;41:577-85. [DOI: 10.1080/08923973.2019.1672178] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
142 Zimmermann-Kogadeeva M, Zimmermann M, Goodman AL. Insights from pharmacokinetic models of host-microbiome drug metabolism. Gut Microbes 2020;11:587-96. [PMID: 31564204 DOI: 10.1080/19490976.2019.1667724] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 3.7] [Reference Citation Analysis]
143 Lubomski M, Davis RL, Sue CM. The gut microbiota: A novel therapeutic target in Parkinson's disease? Parkinsonism & Related Disorders 2019;66:265-6. [DOI: 10.1016/j.parkreldis.2019.08.010] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
144 Cox LM, Abou-El-Hassan H, Maghzi AH, Vincentini J, Weiner HL. The sex-specific interaction of the microbiome in neurodegenerative diseases. Brain Res 2019;1724:146385. [PMID: 31419428 DOI: 10.1016/j.brainres.2019.146385] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
145 Müller T, Thiede HM. Bound, free, and total L-dopa measurement in plasma of Parkinson's disease patients. J Neural Transm (Vienna) 2019;126:1417-20. [PMID: 31396704 DOI: 10.1007/s00702-019-02057-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
146 Tai L, Liaw TS, Lin Y, Nyein HYY, Bariya M, Ji W, Hettick M, Zhao C, Zhao J, Hou L, Yuan Z, Fan Z, Javey A. Wearable Sweat Band for Noninvasive Levodopa Monitoring. Nano Lett 2019;19:6346-51. [DOI: 10.1021/acs.nanolett.9b02478] [Cited by in Crossref: 47] [Cited by in F6Publishing: 55] [Article Influence: 15.7] [Reference Citation Analysis]
147 van de Wouw M, Boehme M, Dinan TG, Cryan JF. Monocyte mobilisation, microbiota & mental illness. Brain Behav Immun 2019;81:74-91. [PMID: 31330299 DOI: 10.1016/j.bbi.2019.07.019] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 6.7] [Reference Citation Analysis]
148 O'Neill C. Gut microbes metabolize Parkinson's disease drug. Science 2019;364:1030-1. [PMID: 31196998 DOI: 10.1126/science.aax8937] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
149 Morales-Briceño H, Fung VSC. You shall not pass! Gut bacteria can convert levodopa to dopamine. Mov Disord 2019;34:986. [PMID: 31206796 DOI: 10.1002/mds.27737] [Reference Citation Analysis]
150 Hitchings R, Kelly L. Predicting and Understanding the Human Microbiome's Impact on Pharmacology. Trends Pharmacol Sci 2019;40:495-505. [PMID: 31171383 DOI: 10.1016/j.tips.2019.04.014] [Cited by in Crossref: 11] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
151 González-arancibia C, Urrutia-piñones J, Illanes-gonzález J, Martinez-pinto J, Sotomayor-zárate R, Julio-pieper M, Bravo JA. Do your gut microbes affect your brain dopamine? Psychopharmacology 2019;236:1611-22. [DOI: 10.1007/s00213-019-05265-5] [Cited by in Crossref: 30] [Cited by in F6Publishing: 39] [Article Influence: 10.0] [Reference Citation Analysis]
152 Leprun PMB, Clarke G. The gut microbiome and pharmacology: a prescription for therapeutic targeting of the gut-brain axis. Curr Opin Pharmacol 2019;49:17-23. [PMID: 31082716 DOI: 10.1016/j.coph.2019.04.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
153 Magistrelli L, Amoruso A, Mogna L, Graziano T, Cantello R, Pane M, Comi C. Probiotics May Have Beneficial Effects in Parkinson's Disease: In vitro Evidence. Front Immunol 2019;10:969. [PMID: 31134068 DOI: 10.3389/fimmu.2019.00969] [Cited by in Crossref: 27] [Cited by in F6Publishing: 42] [Article Influence: 9.0] [Reference Citation Analysis]
154 Lee S, Min K. Drosophila melanogaster as a model system in the study of pharmacological interventions in aging. Translational Medicine of Aging 2019;3:98-103. [DOI: 10.1016/j.tma.2019.09.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
155 [DOI: 10.1101/2020.08.10.20171397] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
156 [DOI: 10.1101/691030] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]